Answers are grounded in this paper and cite their sources.
Scoping review maps definitions, surveillance tools, incidence, and risk factors for CLABSI in ICU settings, highlighting gaps for future guidance.
Central line-associated bloodstream infections (CLABSI) constitute 9.6% of HAIs in ICU patients (Alomari et al., 2025; Sleziak 2025; Anand 2026). CLABSI has a global incidence of 5.05 per 1000 catheter-days in ICUs (Guan 2025). CLABSI lead to high morbidity, mortality and prolonged ICU stays, demanding intensive treatment, escalating healthcare costs and carrying a serious burden (Alomari et al., 2025; Sleziak 2025). It independently elevates mortality rates by 12–25% (Sleziak et al., 2025). CLABSI, which is becoming an increasingly serious condition in intensive care units, requires more urgent intervention than all other healthcare-associated infections, and its prevention is a critical priority for patient safety. Approximately 65–70% of CLABSI cases may be preventable through the implementation of current evidence-based intervention strategies during catheter insertion as well as subsequent continuous catheter care (Sleziak 2025). The World Health Organization (WHO) considers surveillance one of the essential components of effective prevention of HAI. Surveillance systems provide baseline data, detect increases in incidence, and allow comparison over time and between healthcare facilities and enable assessment of the impact of prevention measures (Catho Gaud 2026). Critically ill patients’ high exposure to central venous catheters increases risk, while variation in definitions and surveillance tools across jurisdictions complicates incidence measurement and cross-country comparisons. Despite advances in prevention, CLABSI incidence remains significant, with variability in definitions and surveillance tools across countries. This heterogeneity complicates incidence measurement and benchmarking. A scoping review is therefore appropriate to map the breadth of evidence on CLABSI definitions, surveillance tools, incidence, risk factors, and to identify gaps to guide WG2 harmonization and future trials. This scoping review aims to map existing evidence on CLABSI in ICU settings, focusing on definitions, surveillance approaches, incidence, temporal trends, risk factors and evidence gaps relevant to future harmonisation. The review will follow Arksey and O’Malley’s methodological framework and PRISMA-ScR guidance. Searches will be conducted in PubMed/MEDLINE, CINAHL, Web of Science, Scopus and ProQuest, supplemented by grey literature, reference list screening and manual journal searches. Eligible sources will include reviews, trials, observational studies, quality improvement studies, guidelines, surveillance reports and policy documents published between 2016 and 2026. Findings will be synthesised descriptively and narratively to produce an evidence map and inform minimal dataset development.
No takes yet. Share an insight, caveat, or question.
Vavlukis et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: